Abstract
This study assessed the effects of IP injections of (±) 7-hydroxy-2(N,N-di-n-propylamino)tetralin (7-OH-DPAT), a dopamine agonist that has been reported to have preferential affinity for the dopamine D3 subtype of receptor, on four behavioural procedures in the rat: 1) spontaneous locomotion, 2) electrical self-stimulation of the ventral tegmental area (VTA), using the curve-shift procedure 3) operant responding for food under a progressive-ratio (PR) schedule and 4) induction of stereotypies. The effects of (±) 7-OH-DPAT were compared to the effects of apomorphine, a non-specific DA agonist, and quinpirole, a selective D2/D3 agonist. All three dopamine agonists decreased locomotor activity at low doses (0.01–0.3 mg/kg), and only apomorphine had clear locomotor stimulant effects at the highest dose tested (3 mg/kg). The three drugs dose-dependently depressed VTA self-stimulation in a similar way, with low doses inducing a fairly parallel rightward shift of the frequency/rate curves and higher doses flattening the curves. In contrast, responding for food under the PR schedule appeared to be differentially affected by the three agonists: 7-OH-DPAT induced a biphasic effect, with a maximal decrease in lever-pressing at 0.1 mg/kg, followed by a return to baseline levels with increasing doses (0.3–3 mg/kg); quinpirole showed a tendency to decrease responding over the whole dose-range tested with a maximal effect of about 50% of baseline between 0.25 and 1 mg/kg, and apomorphine dose-dependently decreased responding, with rats ceasing to respond at 0.3 mg/kg. All three DA agonists induced stereotypies, but there was a difference in the maximal stereotypy score induced by each of the ligands: 7-OH-DPAT produced a lower maximal effect than quinpirole or apomorphine. This indicates that each of the three dopamine agonists preferentially induced different types of stereotypies. Together, these data suggest that the putative dopamine D3 agonist 7-OH-DPAT, at low doses, has depressant effects similar to those induced by low doses of the other two DA agonists. Differences in the behavioural effects of higher doses were, however, mostly observed in two procedures, PR responding and induction of stereotypies.
Similar content being viewed by others
References
Ahlenius S, Salmi P (1994) Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol 260:177–181
Ariano MA, Sibley DR (1994) Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes. Brain Res 649:95–110
Arnt J, Hyttel J, Perregaard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur J Pharmacol 133:137–145
Baldessarini RJ, Kula NS, McGrath CR, Bakthavachalam V, Kebabian JW, Neumeyer JL (1993) Isomeric selectivity at dopamine D3 receptors. Eur J Pharmacol 239:269–270
Booth RG, Baldessarini RJ, Marsh E, Owens CE (1994) Actions of (±)-7-hydroxy-N,N-dipropylaminotetralin (7-OH-DPAT) on dopamine synthesis in limbic and extrapyramidal regions of rat brain. Brain Res 662:283–288
Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564: 203–219
Caine SB, Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260:1814–1816
Caine SB, Koob GF (1995) Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat. Behav Pharmacol 6:333–347
Costall B, Naylor RJ, Cannon JG, Lee T (1977) Differentiation of the dopamine mechanisms mediating stereotyped behaviour and hyperactivity in the nucleus accumbens and caudate-putamen. J Pharm Pharmacol 29:337–342
Daly SA, Waddington JL (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other “D-2-like” agonists. Neuropharmacology 32:509–510
Damsma G, Bottema T, Westerink BHC, Tepper PG, Dijkstra D, Pugsley TA, MacKenzie RG, Heffner TG, Wikstrom H (1993) Pharmacological aspects ofR-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol 249:R9-R10
De Fonseca FR, Rubio P, Martin-Calderon JL, Caine SB, Koob GF, Navarro M (1995) The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. Eur J Pharmacol 274:47–55
Dews PB, Wenger GR (1977) Rate-dependency of the behavioral effects of amphetamine. In: Thompson T, Dews PB (eds) Advances in behavioral pharmacology, vol. 1. Academic, New York, pp 167–227
Di Chiara G, Porceddu ML, Vargiu L, Argiolas A, Gessa GL (1976) Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264:564–567
Eilam D, Szechtman H (1989) Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161: 151–157
Feenstra MGP, Sumners C, Goedemoed JH, de Vries JB, Rollema H, Horn AS (1983) A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity. Naunyn-Schmiedeberg's Arch Pharmacol 324:108–115
Fibiger HC, Phillips AG (1988) Mesocorticolimbic dopamine systems and reward. Ann NY Acad Sci 537:206–215
Gallistel CR, Karras D (1984) Pimozide and amphetamine have opposing effects on the reward summation function. Pharmacol Biochem Behav 20:73–77
Gallistel CR, Gomita Y, Yadin E, Campbell KA (1985) Fore brain origins and terminations of the medial forebrain bundle metabolically activated by rewarding stimulation or by reward-blocking doses of pimozide. J Neurosci 5 [5]1246–1261
Gilbert DB, Millar J, Cooper SJ (1995) The putative dopamine D3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res 681:1–7
Gonzalez AM, Sibley DR (1995) [3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. Eur J Pharmacol 272:R1-R3
Herberg LJ, Stephens DN, Franklin KBJ (1976) Catecholamines and self-stimulation: evidence suggesting a reinforcing role for noradrenaline and a motivating role for dopamine. Pharmacol Biochem Behav 4:575–582
Hernandez L, Hoebel BG (1988) Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sci 42:1705–1711
Herroelen L, De Backer J-P, Wilczak N, Flamez A, Vauquelin G, De Keyser J (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 648:222–228
Hillefors-Berglund M, Von Euler G (1994) Pharmacology of dopamine D3 receptors in the islands of Calleja of the rat using quantitative receptor autoradiography. Eur J Pharmacol 261:179–183
Hodos W (1961) Progressive ratio as a measure of reward strength. Science 134:943–944
Kirby KN (1993) Advanced data analysis with SYSTAT. Van Nostrand Reinhold, New York
Landwehrmeyer B, Mengod G, Palacios JM (1993a) Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci 5:145–153
Landwehrmeyer B, Mengod G, Palacios JM (1993b) Dopamine D3 receptor mRNA and binding sites in human brain. Mol Brain Res 18:187–192
Leith NJ (1983) Effects of apomorphine on self-stimulation responding: does the drug mimic the current? Brain Res 277:129–136
Levesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-(3H)hydroxy-N, N-di-n-propyl-2- aminotetralin. Proc Natl Acad Sci USA 89:8155–8159
Liu J-C, Cox RF, Greif GJ, Freedman JE, Waszczak BL (1994) The putative dopamine D3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity. Eur J Pharmacol 264:269–278
Lynch MR, Wise RA (1985) Relative effectiveness of pimozide, haloperidol and trifluoperazine on self-stimulation rate-intensity functions. Pharmacol Biochem Behav 23:777–780
McElroy J, Zeller, K, Amy K, Ward K, Cawley J, Mazzola A, Keim W, Rohrbach K (1993) In vivo agonist properties of 7-hydroxy-N, N-di-N-propyl-2-aminotetralin, a dopamine D3-selective receptor ligand. Drug Dev Res 30:257–259
McElroy J (1994) Discriminative stimulus properties of 7-OH-DPAT, a dopamine D3-selective receptor ligand. Pharmacol Biochem Behav 48:531–533
MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L, Todd RD, O'Malley KL (1994) Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol [Mol Pharmacol Sec] 266:79–85
Mallet PE, Beninger RJ (1994) 7-OH-DPAT produces place conditioning in rats. Eur J Pharmacol 261:R5-R6
Meller E, Bohmaker K, Goldstein M, Basham DA (1993) Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors. Eur J Pharmacol 249:R5-R6
Mulder TB, de Vries JB, Dijkstra D, Wiechers JW, Grol CJ, Horn AS (1987) Further in vitro and in vivo studies with the putative presynaptic dopamine agonistN, N-dipropyl-7-hydroxy-2-aminotetralin. Naunyn Schmiedeberg's Arch Pharmacol 336: 494–501
Murray AM, Ryoo H, Joyce JN (1992) Visualization of dopamine D3-like receptors in human brain with (125l)epidepride. Eur J Pharmacol 227:443–445
Nakajima S, O'Regan NB (1991) The effects of dopaminergic agonists and antagonists on the frequency-response function for hypothalamic self-stimulation in the rat. Pharmacol Biochem Behav 39:465–468
Nakajima S, Liu X, Lau CL (1993) Synergistic interaction of D1 and D2 dopamine receptors in the modulation of the reinforcing effect of brain stimulation. Behav Neurosci 107:161–165
Parsons B, Stanley M, Javitch J (1993) Differential visualization of dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol 234:269–272
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
Poncelet M, Chermat R, Soubrie P, Simon P (1983) The progressive ratio schedule as a model for studying the psychomotor stimulant activity of drugs in the rat. Psychopharmacology 80:184–189
Sahakian BJ, Koob GF (1978) The relationship between pipradrol-induced responding for electrical brain stimulation, stereotyped behaviour and locomotor activity. Neuropharmacology 17:363–366
Schoemaker H (1993) [3H]7-OH-DPAT labels both dopamine D3 receptors andσ sites in the bovine caudate nucleus. Eur J Pharmacol 242:R1-R2
Seeman P, Van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264–270
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151
Sokoloff P, Giros B, Martres MP, Andrieux M, Besancon R, Pilon C, Bouthenet ML, Souil E, Schwartz JC (1992) Localization and function of the D3 dopamine receptor. Arzneimittelforschung 42:224–230
Stahle L, Ungerstedt U (1986) Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by a low dose of apomorphine: implications for the identity of dopamine receptors. Pharmacol Biochem Behav 25:473–480
Starr MS, Starr BS (1989) Behavioural synergism between the dopamine agonists SKF 38393 and LY 171555 in dopamine-depleted mice: antagonism by sulpiride reveals only stimulant postsynaptic D-2 receptors. Pharmacol Biochem Behav 33: 41–44
Stellar JR, Rice MB (1989) Pharmacological basis of intracranial self-stimulation reward. In: JM Liebman, SJ Cooper (eds) The neuropharmacological basis of reward. Oxford University Press, Oxford p 14–65
Svensson K, Carlsson A, Waters N (1994a) Locomotor inhibition by the D3 ligandR-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm [Gen Sect] 95:71–74
Svensson K, Carlsson A, Huff RM, Kling-Petersen T, Waters N (1994b) Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol 263:235–243
Tang L, Todd RD, O'Malley KL (1994) Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther 270:475–479
Timmerman W, Tepper PG, Dijkstra D, Stoelwinder H, Grol CJ, Westerink BHC, Horn AS (1991) Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studied by brain dialysis. Eur J Pharmacol 199:145–151
Timmermans PB, Mathy MJ, Wilffert B, Kalkman HO, Smit G, Dijkstra D, Horn, AS, and Van Zwieten PA (1984) α1/α2-adrenoceptor agonist selectivity of mono- and dihydroxy-2-N,N-di-n-propylaminotetralins. Eur J Pharmacol 97:55–65
Tsuruta K, Frey EA, Grewe CW, Cote TE, Eskay RL, Kebabian JW (1981) Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 292:463–465
Van den Buuse M (1993) Effects of 7-hydroxy-N, N-di-n-propylaminotetralin on behaviour and blood pressure of spontaneously hypertensive rats. Eur J Pharmacol 243:169–177
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Depoortere, R., Perrault, G. & Sanger, D.J. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology 124, 231–240 (1996). https://doi.org/10.1007/BF02246662
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246662